FindTrial
Sign In

Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01600768
Enrollment
100
Registered
2012-05-17
Start date
2012-02-29
Completion date
2015-12-31
Last updated
2012-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-Negative Bacterial Infections

Keywords

focus of study

Brief summary

The purpose of this study is to evaluate the PK/PD parameters, safety and efficacy of extended infusion of beta-lactams in intensive care patients who are infected with Gram-negative bacteremia or pneumonia at National Taiwan University Hospital (NTUH).

Interventions

DRUGBeta-Lactams

infusion time: 30 mins or 1 hr

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (\> 18 years) * Admitted on the intensive care unit * Starting a treatment with beta-lactams antibiotics * Signed informed consent * Expected to live \> 3 days

Exclusion criteria

* renal insufficiency (estimated clearance \< 20 ML /MIN) * renal replacement therapy * ANC \< 1000 103 µl * pregnancy * drug abuse

Design outcomes

Primary

MeasureTime frameDescription
serum concentrations of beta-lactams6 hoursDetermination of serum concentrations of beta-lactams

Countries

Taiwan

Contacts

Primary ContactShu-Wen Lin, Pharm D.
shuwenlin@ntu.edu.tw(02)2312-3456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026